Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Moodys
Express Scripts
Dow
AstraZeneca

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,202,429

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,202,429
Title:Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
Abstract: A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.
Inventor(s): Trese; Michael T. (Novi, MI), Capone, Jr.; Antonio (Novi, MI), Drenser; Kimberly (Novi, MI)
Assignee: RETINAL SOLUTIONS LLC (Ann Arbor, MI)
Application Number:14/733,729
Patent Claims:1. A method of treating edema in a retina of a living subject by tightening inter-cellular junctions in retinal vessel cells or choroidal vessel cells defining a tissue comprising: administering by intraocular injection or solution droplets application to an eye containing the retinal vessel cells or the choroidal vessel cells an effective amount of an N-terminus norrin truncate that has a polypeptide N-terminus cleavage relative to a native norrin protein of up 40 amino acid residues retaining a cysteine-knot motif of the native norrin and capable of binding to the retinal vessel cells or the choroidal vessel cells, or a norrin mutant having at least 85% amino acid identity to SEQ ID NO. 1 and retaining a cysteine-knot motif of the native norrin and capable of binding to the retinal vessel cells or the choroidal vessel cells; and allowing sufficient time for said N-terminus norrin truncate or said norrin mutant to selectively up-regulate gene expression of VE-cadherin and claudin-5 in the retinal vessel cells or the choroidal vessel cells to tighten the inter-cellular junctions of the tissue for prevention of vascular leakage or repair of the vascular leakage to treat the edema in the retina.

2. The method of claim 1, wherein said subject is human.

3. The method of claim 1, wherein said subject is one of: cow, horse, sheep, pig, goat, chicken, cat, dog, mouse, guinea pig, hamster, rabbit, or rat.

4. The method of claim 1, further comprising diagnosing retina edema associated with fluid leakage from a retinal vessel defined by retinal vessel cells prior to the exposing step.

5. The method of claim 1, wherein said N-terminus norrin truncate consists of: a polypeptide of SEQ ID. NO. 2.

6. The method of claim 1, wherein said N-terminus norrin truncate or norrin mutant is selected from the group consisting of SEQ ID. NO. 3, 5, 6, 7, 8, 9, 10, 11, 14, and 16.

7. The method of claim 1, wherein said N-terminus norrin truncate or norrin mutant is selected from the group consisting of SEQ ID. NO. 12, 13, 14, 15, 17, 18, 19, 20, and 21.

8. The method of claim 1, wherein said N-terminus norrin truncate or said norrin mutant is recombinant.

9. The method of claim 1, further comprising bringing a dye into contact with the retinal vessel cells after the allowing sufficient time for said norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 to measure a tightness of the inter-cellular junctions.

10. The method of claim 9, wherein said dye is an immunostain for claudin-5 or VE-cadherin.

11. The method of claim 9, wherein said dye is Evans Blue dye or fluoroscein.

12. The method of claim 1 wherein the tissue is experiencing edema prior to the administering step.

13. A method of treating edema in a retina of a living subject by tightening inter-cellular junctions in retinal vessel cells or choroidal vessel cells defining a tissue comprising: administering by intraocular injection or solution droplets application to an eye containing the retinal vessel cells or the choroidal vessel cells an effective amount of an N-terminus norrin truncate that has a polypeptide N-terminus cleavage relative to a native norrin protein of up 40 amino acid residues retaining a cysteine-knot motif of the native norrin and capable of binding to the retinal vessel cells or the choroidal vessel cells, or a norrin mutant having at least 85% amino acid identity to SEQ ID NO. 1 and retaining a cysteine-knot motif of the native norrin and capable of binding to the retinal vessel cells or the choroidal vessel cells; administering in concert with said N-terminus norrin truncate or norrin mutant and by intraocular injection or solution droplets application to the eye containing the retinal vessel cells or the choroidal vessel cells an effective amount an anti-VEGF agent selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, or a combination thereof and allowing sufficient time for said N-terminus norrin truncate or said norrin mutant to selectively up-regulate gene expression of VE-cadherin and claudin-5 in the retinal vessel cells or the choroidal vessel cells to tighten the inter-cellular junctions of the tissue for prevention of vascular leakage or repair of the vascular leakage to treat the edema in the retina.

Details for Patent 10,202,429

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Sign up for a Free Trial 2039-02-26
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2006-06-30 ⤷  Sign up for a Free Trial 2039-02-26
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2012-08-10 ⤷  Sign up for a Free Trial 2039-02-26
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2016-10-13 ⤷  Sign up for a Free Trial 2039-02-26
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2018-03-20 ⤷  Sign up for a Free Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.